Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
about
Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulationA proteomic investigation of ligand-dependent HSP90 complexes reveals CHORDC1 as a novel ADP-dependent HSP90-interacting proteinExtracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionallyRole of ARF6, Rab11 and external Hsp90 in the trafficking and recycling of recombinant-soluble Neisseria meningitidis adhesin A (rNadA) in human epithelial cellsThe hsp90 molecular chaperone modulates multiple telomerase activities.Heat shock proteins (HSPs) in the homeostasis of regulatory T cells (Tregs)Target therapy in metastatic pheochromocytoma: current perspectives and controversiesPhase I evaluation of STA-1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancerProteome analysis identified the PPARĪ³ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interactionEssential role of the redox-sensitive kinase p66shc in determining energetic and oxidative status and cell fate in neuronal preconditioningDynamic Interaction of Hsp90 with Its Client Protein p53.Heat shock protein 90: translation from cancer to Alzheimer's disease treatment?Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction.Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.Decreased Hsp90 expression in infiltrative lobular carcinoma: an immunohistochemical study.Physiological regulation of Akt activity and stability.17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cellsTargeting the 90 kDa heat shock protein improves photodynamic therapy.Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in miceGeldanamycin and Its Derivatives Inhibit the Growth of Myeloma Cells and Reduce the Expression of the MET Receptor.Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells.Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers.Skp2B overexpression alters a prohibitin-p53 axis and the transcription of PAPP-A, the protease of insulin-like growth factor binding protein 4Hsp90 is required for transfer of the cholera toxin A1 subunit from the endoplasmic reticulum to the cytosol.Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.Effect of a heat shock protein 90-specific inhibitor on the proliferation and apoptosis induced by VEGF-C in cervical cancer cellsA heat-shock protein axis regulates VEGFR2 proteolysis, blood vessel development and repair.Standard of care and promising new agents for triple negative metastatic breast cancer17-allyamino-17-demethoxygeldanamycin treatment results in a magnetic resonance spectroscopy-detectable elevation in choline-containing metabolites associated with increased expression of choline transporter SLC44A1 and phospholipase A2Active participation of cellular chaperone Hsp90 in regulating the function of rotavirus nonstructural protein 3 (NSP3).Hsp90 inhibitor BIIB021 enhances triptolide-induced apoptosis of human T-cell acute lymphoblastic leukemia cells in vitro mainly by disrupting p53-MDM2 balanceProteome interrogation using nanoprobes to identify targets of a cancer-killing molecule.Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.Repercussion of Mitochondria Deformity Induced by Anti-Hsp90 Drug 17AAG in Human Tumor Cells.Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.Role of the novel HSP90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapySurvivin is an essential mediator of arthritis interacting with urokinase signalling.Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma.A Scaffold Merging Approach to Hsp90 C-terminal Inhibition: Synthesis and Evaluation of a Chimeric Library.Molecular chaperones and selection against mutations
P2860
Q21195216-ADE7C421-ADA3-49BC-A8FD-48553EC04129Q24312286-2C0739CE-3A64-479B-B21A-A9707ACC7054Q26991472-C04048D5-AEDA-4124-AA50-BB23D4AE7EF8Q27335545-54E0570A-44FC-4C21-948B-586CE781B0ACQ27930828-D5F3C89E-4C22-4C0D-8AD4-D211956720BEQ28069922-2C934EB0-4D36-400A-A4D8-DCE7A52965D0Q28087343-C12BC6AA-398A-4DF0-BD9F-5A454EAB0F06Q28477773-5C6E964B-EA96-4EA9-9D97-2CD6A5A22B79Q28484038-D3FC6624-DBFF-40EA-9E18-16420F9A6D6DQ28566249-E02014E8-6791-4B70-B8B3-BD5B64C16E9FQ30403624-F59BADD5-9D02-42CC-BC6E-30B49615581DQ30855123-12288D9B-058B-4350-81CB-09811C96FAF6Q33384384-22F20852-8226-4286-839A-AB3A06696A3BQ33390600-FCEB8BA1-250A-49FB-BD71-632C6A025D97Q33651638-54A3FC77-A044-4CE5-B540-BCF23DD34A32Q33680673-0188CAEB-8764-451F-B1F5-47521627C0A6Q33688498-3068CDCD-F3E4-4A8E-AD4B-D7403920F456Q33691235-98ACD715-F910-4ECF-817C-8BBC42481FA9Q33707337-11DF8B28-4CA6-4D09-B119-2516ECA73955Q33789416-8DD73CE8-767C-4E7C-A862-782CBD8F799FQ33864394-F63D30EA-147F-4C32-94EB-399FA7AA94B5Q33889501-C8C309F0-1982-4C5D-B692-3B0333142E9FQ33988397-F53C1A34-888F-40BE-AE87-42BE8307B17EQ34181280-C6F3F994-F589-4A9E-88D9-03D5DDE80DCBQ34249948-30999CD7-05F6-465C-88D9-2B16309FF3B1Q34292365-B58147DA-4F96-464A-9B6E-D3EECD8C5CACQ34472013-BDC2D286-52F7-407A-8EFA-92ADCDD5613BQ34774884-C08F6178-BF76-4DF4-8B81-0336088D8C55Q34989144-C972E6F1-0986-48E5-956B-738AB1186E12Q35011140-9F9E8492-399A-48D3-9BEC-928227D60996Q35044980-3EECA346-9FF0-446C-B564-2F02154E4CD6Q35111764-D959D529-165F-4A9A-B091-B022912F3E92Q35188962-AE5C34F5-9B09-4D89-B516-15DDA9F2B356Q35227454-003CAE5C-6719-41CF-A4BE-5004783FCB6EQ35602561-A0E095DF-5B73-4364-9076-9944F7D36F7DQ35726863-D2E8F812-63F1-43B3-AE23-7A17EC653228Q35893385-6092440A-6CE4-4843-9B58-77DC748FFAF8Q36125143-E5F953B7-FD43-4980-91E4-6C6BE000B6CDQ36378350-BAE72B01-6863-4FC9-A7D9-B50CC7635CF8Q36496399-AD0EEAF5-F80C-4FEF-A50A-4319B6FDF4F3
P2860
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
description
2006 nĆ® lÅ«n-bĆ»n
@nan
2006幓ć®č«ę
@ja
2006幓č«ę
@yue
2006幓č«ę
@zh-hant
2006幓č«ę
@zh-hk
2006幓č«ę
@zh-mo
2006幓č«ę
@zh-tw
2006幓č®ŗę
@wuu
2006幓č®ŗę
@zh
2006幓č®ŗę
@zh-cn
name
Targeting of multiple signalli ...... olecular chaperone inhibitors.
@ast
Targeting of multiple signalli ...... olecular chaperone inhibitors.
@en
type
label
Targeting of multiple signalli ...... olecular chaperone inhibitors.
@ast
Targeting of multiple signalli ...... olecular chaperone inhibitors.
@en
prefLabel
Targeting of multiple signalli ...... olecular chaperone inhibitors.
@ast
Targeting of multiple signalli ...... olecular chaperone inhibitors.
@en
P356
P1476
Targeting of multiple signalli ...... olecular chaperone inhibitors.
@en
P2093
Marissa V Powers
P304
P356
10.1677/ERC.1.01324
P478
13 Suppl 1
P50
P577
2006-12-01T00:00:00Z